Brief: Simcere Pharmaceutical Says SIM0278 Injection (Il-2 Mutant FC Fusion Protein) Obtained Clinical Trial Approval
27/07/2023 16:32
July 27 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* SIM0278 INJECTION (IL-2 MUTANT FC FUSION PROTEIN) OBTAINED
CLINICAL TRIAL APPROVAL ISSUED BY NMPA
Source text for Eikon: ID:nHKS5dYwqD
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660